Sandoz Neupogen Biosimilar Heads To ODAC; Cmte. May Be Students As Much As Advisors

January meeting date suggests FDA’s review of Sandoz’s abridged filgrastim application is on track, but Oncologic Drugs Advisory Committee could be challenged by differences between biosimilar and conventional BLA development.